Centrexion Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$12.6M
- Investors
-
23
Centrexion Therapeutics General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to address the unmet medical need for the treatment of chronic pain. The company offers services that include identifying, developing and commercializing novel, non-opioid and non-addictive therapies like a topical gel, joint or deeper tissue injection, spinal delivery and three separate oral therapies, enabling patients to have safe, effective and durable treatments.
Contact Information
Website
www.centrexion.comCorporate Office
- One Boston Place
- Suite 3520
- Boston, MA 02108
- United States
Corporate Office
- One Boston Place
- Suite 3520
- Boston, MA 02108
- United States
Centrexion Therapeutics Timeline
Centrexion Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 27-Nov-2023 | $12.6M | Completed | Generating Revenue | ||
| 10. Debt - General | 12-Jul-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 10-Aug-2022 | Completed | Generating Revenue | |||
| 8. Grant | 30-Sep-2021 | Completed | Generating Revenue | |||
| 7. IPO | 05-May-2021 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC (Series E) | 22-Jan-2021 | Completed | Generating Revenue | |||
| 5. Mezzanine | 28-Jun-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 02-Jan-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 30-Dec-2016 | $45.1M | $68.8M | Completed | Clinical Trials - Phase 1 | |
| 2. Accelerator/Incubator | 09-Sep-2014 | $150K | $23.6M | Completed | Clinical Trials - Phase 1 |
Centrexion Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 21,999,999 | $0.001000 | 8% | $1.75 | $1.75 | 1x | $1.75 | 11.49% |
| Series A | 5,000,000 | $0.001000 | 8% | $1.75 | $1.75 | 1x | $1.75 | 2.61% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Centrexion Therapeutics Comparisons
Industry
Financing
Details
Centrexion Therapeutics Competitors (49)
One of Centrexion Therapeutics’s 49 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Citius Pharma | Corporation | Cranford, NJ | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| IPI Legacy Liquidation | Formerly VC-backed | Seattle, WA |
Centrexion Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Centrexion Therapeutics Patents
Centrexion Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240383892-A1 | Particles of imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | Pending | 17-May-2023 | ||
| US-12268679-B1 | Compositions and methods for epidural administration of mcoppb for pain relief | Active | 28-Jun-2021 | ||
| US-20210322412-A1 | Methods and compositions for treating a coronavirus infection | Inactive | 20-Apr-2020 | ||
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | Active | 18-Jan-2019 | ||
| US-11447444-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | Active | 18-Jan-2019 | C07D211/26 |
Centrexion Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Centrexion Therapeutics Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Plutus Investment Group | Family Office | |||
| Hibiscus Capital Management | Venture Capital | Minority | ||
| National Institutes of Health | Government | |||
| Eli Lilly and Company | Corporation | |||
| Exome Asset Management | Asset Manager |
Centrexion Therapeutics Investments & Acquisitions (2)
Centrexion Therapeutics’s most recent deal was a Corporate Asset Purchase with Boehringer Ingelheim (three new analgesic candidates). The deal was made on 30-Mar-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Boehringer Ingelheim (three new analgesic candidates) | 30-Mar-2016 | Corporate Asset Purchase | Buildings and Property | ||
| Vallinex | 20-Nov-2013 | Merger/Acquisition | Pharmaceuticals |
Centrexion Therapeutics FAQs
-
When was Centrexion Therapeutics founded?
Centrexion Therapeutics was founded in 2013.
-
Where is Centrexion Therapeutics headquartered?
Centrexion Therapeutics is headquartered in Boston, MA.
-
What is the size of Centrexion Therapeutics?
Centrexion Therapeutics has 23 total employees.
-
What industry is Centrexion Therapeutics in?
Centrexion Therapeutics’s primary industry is Drug Discovery.
-
Is Centrexion Therapeutics a private or public company?
Centrexion Therapeutics is a Private company.
-
What is Centrexion Therapeutics’s current revenue?
The current revenue for Centrexion Therapeutics is .
-
How much funding has Centrexion Therapeutics raised over time?
Centrexion Therapeutics has raised $279M.
-
Who are Centrexion Therapeutics’s investors?
Plutus Investment Group, Hibiscus Capital Management, National Institutes of Health, Eli Lilly and Company, and Exome Asset Management are 5 of 23 investors who have invested in Centrexion Therapeutics.
-
Who are Centrexion Therapeutics’s competitors?
Mesoblast, Vertex Pharmaceuticals, Citius Pharma, Kite Pharma, and IPI Legacy Liquidation are some of the 49 competitors of Centrexion Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
